Evidence map›Paper›PMID 38930915›Full record

ArticleMolecules (Basel, Switzerland)2024

Design and Synthesis of Thiourea-Conjugating Organic Arsenic D-Glucose with Anticancer Activities.

Boqiao Fu, Wenxuan Liu, Yufeng Wang, Guorui Li, Yingsha Wang, Xinyuan Huang, Hongan Shi, Caiqin Qin

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Selenium/Zinc nanocomposite (Se/Zn NC) bioengineered byThe Libyan journal of medicine · 2026
    Article
  2. PROTACs in cancer therapy: targeted degradation of GPX4, PARP and epigenetic regulators.Journal of enzyme inhibition and medicinal chemistry · 2026
    Review
  3. Identification of selectiveRSC advances · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Thioflavonols as potent α-glucosidase inhibitors:Future medicinal chemistry · 2025
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Boqiao FuCollege of Chemistry and Materials Science, Hubei Engineering University, Xiaogan 432000, China.ORCID 0000-0002-7022-6051
Wenxuan LiuCollege of Chemistry and Materials Science, Hubei Engineering University, Xiaogan 432000, China.
Yufeng WangCollege of Chemistry and Materials Science, Hubei Engineering University, Xiaogan 432000, China.
Guorui LiHunan Provincial Key Laboratory of the Research and Development of Novel Pharmaceutical Preparations, the "Double-First Class" Application Characteristic Discipline of Hunan Province (Pharmaceutical Science), Changsha Medical University, Changsha 410219, China.ORCID 0000-0002-3130-5793
Yingsha WangState Key Laboratory for Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering, School of Biomedical Sciences, Hunan University, Changsha 410082, China.ORCID 0000-0001-8874-9814
Xinyuan HuangHubei Key Laboratory of Quality Control of Characteristic Fruits and Vegetables, College of Life and Technology, Hubei Engineering University, Xiaogan 432000, China.
Hongan ShiHubei Key Laboratory of Quality Control of Characteristic Fruits and Vegetables, College of Life and Technology, Hubei Engineering University, Xiaogan 432000, China.
Caiqin QinCollege of Chemistry and Materials Science, Hubei Engineering University, Xiaogan 432000, China.ORCID 0009-0005-5887-6325

Funding

Natural Science Foundation of Xiaogan, China XGKJ2019010046the Natural Science Foundation of China 21807029the Undergraduate Innovation and Entrepreneurship Foundation of Hubei Province, China S202310528032
6 · The paper itself

Abstract

Organic arsenic compounds such as

Indexed as

Antineoplastic AgentsDrug DesignThioureaArsenicalsCell Line, TumorCell ProliferationGlucoseHCT116 CellsHumansMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsArsenicalsGlucoseThiourea(1,3,2-dithiarsinan-2-yl) aniline2,3,4,6-O-tetra acetyl-α-anticancer">d-glucopyranoseHCT-116thiourea

Identifiers

PMID38930915
PMCPMC11206549

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.